ISPOR Asia Pacific Summit 2026

Bial announced the completion of the treatment period in its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who carry a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene, referred to as GBA-PD. The 78-week double-blind treatment pha...

An analysis of 1.2 million days of data from 2,596 women across 42,759 menstrual cycles demonstrates that cycle length strongly influences the magnitude of fluctuations in cardiorespiratory biometrics, while shorter sleep durations correlate with greater cycle length deviation. Resting heart rate...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of KEYTRUDA (pembrolizumab), including its subcutaneous formulation KEYTRUDA SC, combined with Padcev (enfortumab vedotin-ejfv) as neoadjuvant treatment followed b...